Ingevity (NGVT) is back in focus after its 29 July 2026 earnings report, which showed net income of US$35.3 million for the second quarter and the completion of a multi year share repurchase program.
See our latest analysis for Ingevity.
Ingevity's latest earnings and completed buyback arrive after a period of strong momentum, with the share price up 21.67% year to date and a 1 year total shareholder return of 80.97%, signaling investors have recently reassessed the company more positively.
If this kind of re rating has you thinking about what else might be moving, it could be a good time to scan the market using our screener for 18 top founder-led companies
After a 1 year total return of 80.97% and a completed buyback that retired about 12.01% of its stock, Ingevity now looks very different. Investors may now be asking whether the current valuation offers enough potential upside to justify taking on new risk.
Most Popular Narrative: 17.9% Undervalued
Analysts see fair value for Ingevity at $89, which sits well above the latest close of $73.11. The gap rests on a specific earnings and margin story that goes beyond the recent buyback headlines.
Accelerated portfolio repositioning and the advanced-stage divestiture of non-core, lower-margin businesses (Industrial Specialties and CTO refinery) are expected to drive a step-change in margin profile, enabling greater focus and capital allocation toward higher-growth, value-added specialty chemicals, supporting both revenue quality and sustained EBITDA margin improvement. Substantial investments in innovation and engineered additives, especially in applications such as EV battery materials (via the Nexeon partnership) and process purification, position Ingevity to capture new demand arising from the increased global focus on sustainability and decarbonization, providing future top-line growth opportunities as industries transition to green technologies.
Analysts are effectively pricing Ingevity around a future where margins are far higher, earnings are rebuilt from a low base, and the P/E multiple shifts to match that outlook. It may be useful to examine which profit assumptions, revenue profile, and discount rate sit underneath that $89 fair value and explain the 17.9% gap.
Result: Fair Value of $89 (UNDERVALUED)
Have a read of the narrative in full and understand what's behind the forecasts.
However, this Ingevity narrative still faces pressure from the weaker Advanced Polymer Technologies segment and ongoing exposure to cyclical industrial and automotive end markets.
Find out about the key risks to this Ingevity narrative.
Another View on Ingevity’s Valuation
The SWS DCF model points to a very different picture for Ingevity. On this view, the stock at $73.11 sits well below an estimated future cash flow value of $165.96, which implies a very large gap. That could represent opportunity, or it could signal that the cash flow assumptions are too optimistic.
Before relying on this model, it is worth understanding how sensitive it is to margin, growth, and discount rate inputs. Look into how the SWS DCF model arrives at its fair value.
Next Steps
If this balanced mix of optimism and caution around Ingevity has you thinking, now is the moment to test the numbers yourself. To weigh both sides of the story and form your own view, start with the 4 key rewards and 2 important warning signs.
Looking for more investment ideas beyond Ingevity?
If you are serious about building a stronger portfolio, now is the time to widen your search using focused stock ideas from the Simply Wall St screener.
- Spot potential mispricings by checking stocks that appear to trade below their estimated worth through the 55 high quality undervalued stocks.
- Strengthen your income stream by reviewing companies with robust payout profiles via the 9 dividend fortresses.
- Reduce portfolio stress by scanning for companies that carry lower overall risk using the 81 resilient stocks with low risk scores.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com